RR MedSciences has released new peer-reviewed research (Redox Biology Journal, January 2021) of its RM191A compound, containing highly active copper, that prevents the build-up of free radicals that cause skin damage after UV exposure and even the DNA damage that leads to skin cancer and photo-aging. It is proven to have multiple important health benefits due to its mode of action, including faster wound healing, reduced inflammation and related pain.
The RM191A compound, which has been developed in a topical gel, is the focus of the newly published research. Multiple world-class Australian researchers have collaborated with RR MedSciences over the past six years to define the compounds’ activities.
Beneficial effects of RM191A include:
Anti-inflammatory activity: Multiple tests showed the compound dramatically reduced inflammation by 75%. The compound works by neutralising free radicals and regulating inflammatory signaling.
Free radical neutralising: The new compound acts to quench free-radical activity, outperforming the body’s own enzymes (SOD) by 10-30 times. Unlike SOD, it also reduces nitrogen free radicals, that are related to pain.
Improved healing : In tests of skin injury, the gel improved wound healing, reducing healing time by nearly half, from 23 days to 10-12 days.
Skin and DNA protective: When tested on human skin in the laboratory, the compound - RM191A - significantly inhibits UV-induced (sun) DNA and skin damage, in both the epidermis and dermis.
The research indicates the compound may have a wide variety of applications in areas such as skin disease and skin damage, trauma, post-operative and wound healing, and aged care.
RR MedSciences is a Sydney based biotech that developed the proprietary compound RM191A, which has advanced to Phase 2 clinical studies for the specific treatment of neuropathic pain. The company intends to further research associated with the results published in Redox Biology including DNA skin protection, wound healing, and inflammatory and free-radical driven disease.
Please join our email list for company news and updates.